PTC
ACAD icon

Private Trust Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Private Trust Company’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51
Closed -$847 – 2467
2025
Q1 		$847 Buy
+51
New +$926 ﹤0.01% 2381
2014
Q4 		– Sell
-40
Closed -$1K – 304
2014
Q3 		$1K Hold
40
– – ﹤0.01% 1695
2014
Q2 		$1K Sell
40
-8
-17% -$167 ﹤0.01% 1717
2014
Q1 		$1K Sell
48
-10
-17% -$253 ﹤0.01% 1596
2013
Q4 		$1K Hold
58
– – ﹤0.01% 1600
2013
Q3 		$2K Hold
58
– – ﹤0.01% 1382
2013
Q2 		$1K Buy
+58
New +$799 ﹤0.01% 1498

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Private Trust Company's ACAD Position: Q2 2025 in Review

Private Trust Company sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 51 shares — an estimated $847 sold.

Private Trust Company first reported a position in ACAD in Q2 2013 and held it in 7 quarters. The position peaked at $2K in Q3 2013. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Private Trust Company reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Private Trust Company sold 51 Acadia Pharmaceuticals shares in Q2 2025, an estimated $847.
  • Private Trust Company first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Private Trust Company's Acadia Pharmaceuticals position peaked at $2K in Q3 2013.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Private Trust Company's 13F filing for Q2 2025, filed 29 Jul 2025.